News Quantified

RYTM – rhythm pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments [Yahoo! Finance]

Rhythm Pharmaceuticals Announces Changes to Board of Directors [Yahoo! Finance]

Rhythm Pharmaceuticals Announces Changes to Board of Directors

Is This Weight Loss Drug Stock a Buy After a New Approval? [Yahoo! Finance]

-3.7%

BEAT

-7.5%

MISS

-3.7%

MISS

8.4%

MISS

Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Mazabraud Yann

Form 3 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J

Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J

Form 8-K RHYTHM PHARMACEUTICALS, For: Apr 01

Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: VANGUARD GROUP INC

Top News Gainers

8/7 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities 14.9%

3/16 Form 4 RHYTHM PHARMACEUTICALS, For: Mar 13 Filed by: Smith Hunter C 14.5%

10/15 Form 8-K RHYTHM PHARMACEUTICALS, For: Oct 15 13.4%

10/18 Form 3 RHYTHM PHARMACEUTICALS, For: Oct 16 Filed by: RA Capital Healthcare Fund LP 10.2%

4/9 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.0%

11/22 Form 4 RHYTHM PHARMACEUTICALS, For: Nov 20 Filed by: Foley Todd 6.3%

3/2 Q4/2019 12/31/2019 EPS -0.780 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%

12/5 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes 6.0%

2/25 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference 5.5%

3/30 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities 5.1%

Top News Decliners

8/7 Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 07 -9.8%

9/25 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -8.5%

1/10 Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 10 -5.1%

2/26 Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 20 -5.0%

4/30 Form 4 RHYTHM PHARMACEUTICALS, For: Apr 28 Filed by: Foley Todd -4.7%

4/29 Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 17 -4.7%

3/18 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome -4.6%

7/29 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results -4.2%

6/21 Form 3 RHYTHM PHARMACEUTICALS, For: Jun 19 Filed by: GOOD JENNIFER L -4.1%

1/6 Rhythm Pharmaceuticals Announces Leadership Transition -4.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day